Neuropace Valuation
| NPCE Stock | USD 13.56 -0.26 -1.88% |
Macroaxis currently views Neuropace as undervalued, with a model-derived Real Value of $14.51 per share versus a market price of $13.56. The model weighs Neuropace fundamentals - including profit margin of -21%, current valuation of $487.51M, and return on equity of -1.59% - alongside its technical indicators and probability of bankruptcy.
Undervalued
Today
At the moment, Neuropace's price fluctuation remains Low. For valuation purposes, Macroaxis measures Neuropace over a 3 months time horizon. A broader horizon usually helps the model produce a more dependable value estimate over time.
At a high level, the fair value of the Neuropace stock represents what a buyer may pay to obtain meaningful control of Neuropace. The market value of Neuropace Stock is set by trading activity as buyers and sellers negotiate price in real time. Its market price can differ from intrinsic value, which may create an opportunity if price and value converge over time. | Historical | Market 13.56 | Real 14.51 | Hype 13.56 | Naive 13.39 |
The intrinsic value of Neuropace's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as.
Understanding the potential upside and downside for Neuropace is essential before adding it to a portfolio. The fair value of Neuropace stock is influenced by both quantitative metrics and market sentiment.Valuation Framework, Methodology & Assumptions
Neuropace is a small-cap equity in Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care categories. Peer comparison highlights relative pricing efficiency. Neuropace currently trades at P/B of 25.1, P/S of 4.78, enterprise value of 487.51 M.
For Neuropace, this section uses periodic company reporting and market reference feeds with Macroaxis normalization rules applied to keep cross-asset comparisons consistent. Intraday timing differences may exist. Valuation outputs are model-derived and depend on published assumptions and reference inputs.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardPopular Tools for Neuropace Stock analysis
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |